F
Francois-Xavier Mahon
Researcher at University of Bordeaux
Publications - 293
Citations - 12100
Francois-Xavier Mahon is an academic researcher from University of Bordeaux. The author has contributed to research in topics: Imatinib mesylate & Myeloid leukemia. The author has an hindex of 44, co-authored 282 publications receiving 10491 citations. Previous affiliations of Francois-Xavier Mahon include University of Thessaly & Imperial College Healthcare.
Papers
More filters
Journal ArticleDOI
Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)
François Guilhot,Francois-Xavier Mahon,Joelle Guilhot,Francoise Rigual-Huguet,Frédéric Maloisel,Philippe Rousselot,Martine Gardembas,Selim Corm,Agnès Guerci,Anne Vekhoff,Gabriel Etienne,Laurence Legros,Jean-Jacques Kiladjian,Eric Jourdan,Michele Schoenwald,Marc G. Berger,Virginie Eclache,Catherine Roche-Lestienne,Franck E. Nicolini,Claude Preudhomme +19 more
TL;DR: The increased dose of IM or a combination regimen would be considered as promising if it increased the 4 log reduction response rate by at least 20 percentage points, e.g. from 15% to 35%, with an acceptable tolerability.
Journal ArticleDOI
Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia
Jean-Michel Boiron,Francis Belloc,Marion Montastruc,Pascale Cony-Makhoul,Patrice Dumain,Gerald Marit,Francois-Xavier Mahon,Maryse Puntous,F. Lopez,Francis Lacombe,Josy Reiffers +10 more
TL;DR: The higher Acc of idarubicin than DNR seen in fresh leukemic cells could explain the better clinical efficacy of IDA reported in patients with ANLL.
Journal ArticleDOI
Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.
Sebastien Rinaldetti,Markus Pfirrmann,Kirsi Manz,Joelle Guilhot,Christian Dietz,Panayiotidis Panagiotidis,Birgit Spiess,Wolfgang Seifarth,Alice Fabarius,Martin Müller,Maria Pagoni,Maria Dimou,Jolanta Dengler,Cornelius F. Waller,Tim H. Brümmendorf,Regina Herbst,Andreas Burchert,Carsten Janβen,Maria Elisabeth Goebeler,Philipp J. Jost,Stefan Hanzel,Philippe Schafhausen,Gabriele Prange-Krex,Thomas Illmer,Viktor Janzen,Martine Klausmann,Robert Eckert,Gerd Büschel,Alexander Kiani,Wolf-Karsten Hofmann,Francois-Xavier Mahon,Susanne Saussele +31 more
TL;DR: The transcript levels of the efflux transporter ABCG2 predicted TFR after TKI discontinuation, and was predictive for treatment‐free remission in Cox regression analysis.
Journal ArticleDOI
Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
Journal ArticleDOI
All-trans retinoic acid potentiates the inhibitory effects of interferon alpha on chronic myeloid leukemia progenitors in vitro.
Francois-Xavier Mahon,Chahine H,C. Barbot,V. Pigeonnier,B. Jazwiec,Josy Reiffers,Jean Ripoche +6 more
TL;DR: The results indicate that the combination of IFNα and ATRA effectively inhibits CFU-GM colony formation in CML and suggest that it has a potential interest for the treatment of CML.